ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,405
-0,67%
Bitcoin
67 632,40
-1,07%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. Matinas Biopharma Holdings Inc (MTNB)

  7. Matinas Biopharma Holdings Inc (MTNB) Actualités

MTNB

Matinas Biopharma (MTNB)

Matinas Biopharma Holdings Inc
De:
Trier par:
 Showing the most relevant articles for your search:AMEX:MTNB
DateHeureSourceTitreSymboleSociété
16/05/202413h00GlobeNewswire Inc.New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024AMEX:MTNBMatinas Biopharma Holdings Inc
09/05/202422h06Edgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
09/05/202422h05GlobeNewswire Inc.Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateAMEX:MTNBMatinas Biopharma Holdings Inc
09/05/202422h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:MTNBMatinas Biopharma Holdings Inc
07/05/202414h00GlobeNewswire Inc.Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual MeetingAMEX:MTNBMatinas Biopharma Holdings Inc
02/05/202413h00GlobeNewswire Inc.Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024AMEX:MTNBMatinas Biopharma Holdings Inc
30/04/202414h00GlobeNewswire Inc.In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and ChemotherapyAMEX:MTNBMatinas Biopharma Holdings Inc
03/04/202414h30GlobeNewswire Inc.Matinas BioPharma Prices $10 Million Registered Direct OfferingAMEX:MTNBMatinas Biopharma Holdings Inc
27/03/202421h05GlobeNewswire Inc.Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateAMEX:MTNBMatinas Biopharma Holdings Inc
25/03/202413h00GlobeNewswire Inc.Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationAMEX:MTNBMatinas Biopharma Holdings Inc
22/03/202414h15GlobeNewswire Inc.Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseAMEX:MTNBMatinas Biopharma Holdings Inc
22/03/202411h30GlobeNewswire Inc.Matinas BioPharma Regains Compliance with NYSE American Continued Listing StandardsAMEX:MTNBMatinas Biopharma Holdings Inc
26/02/202414h00GlobeNewswire Inc.Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical ResolutionAMEX:MTNBMatinas Biopharma Holdings Inc
20/02/202413h30GlobeNewswire Inc.Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisAMEX:MTNBMatinas Biopharma Holdings Inc
03/01/202413h00GlobeNewswire Inc.Matinas BioPharma to Present at Biotech Showcase 2024AMEX:MTNBMatinas Biopharma Holdings Inc
27/12/202313h30GlobeNewswire Inc.Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small OligonucleotidesAMEX:MTNBMatinas Biopharma Holdings Inc
21/12/202313h30GlobeNewswire Inc.Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDAAMEX:MTNBMatinas Biopharma Holdings Inc
16/12/202303h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
08/11/202322h05GlobeNewswire Inc.Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business UpdateAMEX:MTNBMatinas Biopharma Holdings Inc
07/11/202313h30GlobeNewswire Inc.Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma ModelAMEX:MTNBMatinas Biopharma Holdings Inc
01/11/202312h00GlobeNewswire Inc.Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023AMEX:MTNBMatinas Biopharma Holdings Inc
11/10/202316h25AllPennyStocks.comBiotech Catches Massive Premarket BidAMEX:MTNBMatinas Biopharma Holdings Inc
11/10/202313h30GlobeNewswire Inc.Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical ResolutionAMEX:MTNBMatinas Biopharma Holdings Inc
28/09/202313h00GlobeNewswire Inc.Matinas BioPharma to Present at Two Investment Conferences in October 2023AMEX:MTNBMatinas Biopharma Holdings Inc
27/09/202313h00GlobeNewswire Inc.Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeekAMEX:MTNBMatinas Biopharma Holdings Inc
22/09/202323h25GlobeNewswire Inc.Matinas BioPharma Announces Notification of NYSE American Continued Listing DeficiencyAMEX:MTNBMatinas Biopharma Holdings Inc
21/09/202315h35GlobeNewswire Inc.Dawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceAMEX:MTNBMatinas Biopharma Holdings Inc
19/09/202323h25Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:MTNBMatinas Biopharma Holdings Inc
08/09/202323h15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsAMEX:MTNBMatinas Biopharma Holdings Inc
06/09/202313h00GlobeNewswire Inc.Matinas BioPharma to Participate in the H.C. Wainwright Global Investment ConferenceAMEX:MTNBMatinas Biopharma Holdings Inc
 Showing the most relevant articles for your search:AMEX:MTNB

Dernières Valeurs Consultées

USOTC
JKELF
John Keells (PK)
TSXV
SCRS.P
St Charles Resources
HITB
CCEUSD
CloudCoin Etherium
TG
92P
AMMO
NASDAQI
YLDANTR
ISE High Income Net Tota...
TG
ASZ1
Alimera Sciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés